We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback